In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp

2020 ◽  
Vol 55 (2) ◽  
pp. 105864
Author(s):  
Aki Yoneda ◽  
Robert Thänert ◽  
Carey-Ann D. Burnham ◽  
Gautam Dantas
Keyword(s):  
Staphylococcus Aureus ◽  
Combination Therapy ◽  
Staphylococcus Epidermidis ◽  
Vancomycin Resistant Enterococcus ◽  
In Vitro Activity ◽  
Triple Combination ◽  
Triple Combination Therapy ◽  
Enterococcus Spp ◽  
Vancomycin Resistant

Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin

Apmis ◽  
2010 ◽  
Vol 118 (1) ◽  
pp. 66-73 ◽  
Author(s):  
MATHIAS RATHE ◽  
LISE KRISTENSEN ◽  
SVEND ELLERMANN-ERIKSEN ◽  
MARIANNE KRAGH THOMSEN ◽  
HELGA SCHUMACHER
Keyword(s):  
Susceptibility Testing ◽  
Vitro Activity ◽  
Vancomycin Resistant Enterococcus ◽  
In Vitro Activity ◽  
Enterococcus Spp ◽  
Vancomycin Resistant

scholarly journals Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model

2016 ◽  
Vol 60 (5) ◽  
pp. 3178-3182 ◽  
Author(s):  
Megan K. Luther ◽  
Louis B. Rice ◽  
Kerry L. LaPlante
Keyword(s):  
Combination Therapy ◽  
Enterococcus Faecalis ◽  
Pharmacodynamic Model ◽  
Infection Model ◽  
Vancomycin Resistant Enterococcus ◽  
Content Type ◽  
Time Profiles ◽  
Concentration Time ◽  
Vancomycin Resistant

ABSTRACTAmpicillin-ceftriaxone combination therapy has become a predominant treatment for seriousEnterococcus faecalisinfections, such as endocarditis. Unfortunately, ceftriaxone use is associated with future vancomycin-resistant enterococcus colonization. We evaluatedE. faecalisin anin vitropharmacodynamic model against simulated human concentration-time profiles of ampicillin plus ceftaroline, cefepime, ceftriaxone, or gentamicin. Ampicillin-cefepime and ampicillin-ceftaroline demonstrated activities similar to those of ampicillin-ceftriaxone againstE. faecalis.

scholarly journals Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens

2000 ◽  
Vol 44 (12) ◽  
pp. 3447-3450 ◽  
Author(s):  
D. R. Snydman ◽  
N. V. Jacobus ◽  
L. A. McDermott ◽  
J. R. Lonks ◽  
J. M. Boyce
Keyword(s):  
Staphylococcus Aureus ◽  
Antibacterial Activity ◽  
Streptococcus Pneumoniae ◽  
Calcium Concentration ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Methicillin Resistant ◽  
Vancomycin Resistant ◽  
Gram Positive Cocci

ABSTRACT The in vitro activity of daptomycin against 224 current gram-positive clinical isolates including vancomycin-resistantEnterococcus faecium (VREF), methicillin-resistantStaphylococcus aureus (MRSA), methicillin-resistantStaphylococcus spp. (MRSS), and penicillin-resistantStreptococcus pneumoniae (PRSP) was evaluated. The MICs at which 90% of isolates are inhibited for daptomycin and vancomycin, respectively, were as follows: MRSA, 1 and 2 μg/ml; MRSS, 1 and 4 μg/ml; PRSP, 1 and 0.5 μg/ml; and VREF, 2 and >64 μg/ml. Daptomycin was bactericidal against 82% of 17 VREF isolates. The antibacterial activity of daptomycin was strongly dependent on the calcium concentration of the medium. Daptomycin was active against all gram-positive cocci tested.

scholarly journals In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates

2010 ◽  
Vol 54 (7) ◽  
pp. 3027-3030 ◽  
Author(s):  
Louis Saravolatz ◽  
Joan Pawlak ◽  
Leonard Johnson
Keyword(s):  
Staphylococcus Aureus ◽  
Treatment Option ◽  
Bactericidal Activity ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Methicillin Resistant ◽  
Vancomycin Resistant

ABSTRACT This study assessed the in vitro activities of ceftaroline and five comparator agents against a collection of Staphylococcus aureus isolates. Ceftaroline demonstrated potent activity against community-associated methicillin-resistant S. aureus (CA-MRSA) isolates and showed bactericidal activity against vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA), heteroresistant VISA (hVISA), and daptomycin-nonsusceptible S. aureus (DNSSA) isolates. Ceftaroline may represent a bactericidal treatment option for infections caused by these pathogens.

Sign in / Sign up

Export Citation Format

Share Document